Pinealon: A Peptide Bioregulator With Preclinical-Only Data
A Khavinson-group tripeptide bioregulator, studied preclinically for neuroprotective and cognitive-aging effects.
What is Pinealon?
Pinealon is a synthetic tripeptide (Glu-Asp-Arg, abbreviated EDR) developed by Vladimir Khavinson's research group in St. Petersburg — the same lab behind Epithalon. It belongs to a family of short 'peptide bioregulators' the group proposes act by binding DNA promoter regions to modulate gene transcription, a mechanistic hypothesis that remains contested outside that research tradition. Pinealon is studied primarily in preclinical/animal models for neuroprotective and cognitive-aging effects. It's sold only as a research compound; no FDA approval or large human trial exists.
Quick facts
- Molecular Formula
- C15H26N6O8
- Molecular Weight
- 418.40 g/mol
- CAS Number
- 175175-23-2
- Sequence
- Glu-Asp-Arg (EDR)
- Class
- Synthetic tripeptide bioregulator (Khavinson group)
- Brand Names
- No trademarked brand — sold as a research compound
- Legal Status
- Not FDA-approved for human use — research use only (RUO)
- Category
- Longevity & Healthspan
- Storage
- Store the lyophilized vial refrigerated (2-8°C) or at -20°C, away from light. Once reconstituted, keep refrigerated at 2-8°C and use promptly.
Dosing at a glance
20mg vial + 2mL bacteriostatic water = 10,000mcg/mL. Run the numbers in the reconstitution calculator.
Doses shown are those reported in published research, not a recommendation.
Pinealon Mechanism of Action
A Khavinson-Group Peptide Bioregulator
Pinealon (EDR: Glu-Asp-Arg) is a synthetic tripeptide from the same research tradition as Epithalon — the 'peptide bioregulator' family developed by Vladimir Khavinson's group. The proposed mechanism is that short peptides like EDR bind complementarily to DNA promoter regions, modulating gene transcription directly — a hypothesis distinct from the receptor-agonist mechanisms most peptides in this catalog use, and one that remains contested and unreplicated outside the originating research group.
Neuroprotection Research Focus
Pinealon-specific research centers on neuroprotective and cognitive-aging effects in animal models, positioned within the Khavinson group's broader work on organ-specific 'bioregulator' peptides (Pinealon for brain/pineal tissue, similar to how their other tripeptides target other organ systems).
Pinealon Dosage and Protocols
Khavinson-Style Cycling Protocol
Vendor/research-typical dosing mirrors the Epithalon convention: 5–10mg daily subcutaneous or intranasal for a 10–20 day course, cycled rather than used continuously. This comes from the originating research group's protocol design, not a formal human dose-finding trial.
Pinealon Side Effects and Safety
Limited Safety Data
No formal human safety or tolerability data exists for Pinealon at scale. Pregnancy and active malignancy are treated as precautionary contraindications, consistent with other short bioregulator peptides in this catalog with a similarly thin safety record.
Pinealon Research Evidence
Narrow, Single-Group Evidence Base
Nearly all published Pinealon research originates from the Khavinson group and affiliated Russian institutions, using older publication standards and small sample sizes, mostly in animal models. Independent replication outside this research tradition is minimal, and no modern, controlled human trial exists.
Regulatory and Legal Status
Pinealon has no FDA-approved indication and is not approved for human consumption. It is sold exclusively as a research-grade compound (RUO). Researchers and users should verify the legal status of Pinealon in their jurisdiction prior to purchase or use.
Pinealon Stacking and Combinations
Pinealon + Epithalon + DSIP
Pinealon is frequently sold and used alongside Epithalon and DSIP in longevity/circadian research protocols — all three come from short-peptide or sleep-regulatory research traditions and are commonly bundled by vendors as a combo. No formal trial data exists for any combination.
Pinealon Pharmacokinetics
No Published Half-Life
No study has directly measured Pinealon's plasma half-life in humans. Based on the general pharmacokinetics of short, unmodified peptides, its circulating half-life is expected to be on the order of minutes — an extrapolation, not a confirmed measurement.
Contraindications
- pregnancy
- active malignancy
Frequently asked questions
What is a typical Pinealon dose?
Published research protocols report 5–10 mg, daily, 10–20 day cycles. This is the range described in the literature, not a recommendation.
What is the half-life of Pinealon?
Expected on the order of minutes (unmodified short peptide) — no direct human plasma half-life study has been published.
Is Pinealon backed by strong evidence?
Pinealon carries a REGEN research grade of F. REGEN Research Tier F — no independent human evidence — a peptide bioregulator sold ahead of its data.
How is Pinealon administered?
Routes reported in the literature: subcutaneous, intranasal.
Who should avoid Pinealon?
Contraindications noted in the literature include pregnancy, active malignancy.